Table 1

Clinicopathological characteristics of 20 breast tumors.

Characteristic

Total N = 20

%

HER2+ N = 9 (%)

HER2- N = 11 (%)


Median age (range)

58.5 (35, 76)

57 (35, 73)

59 (38, 76)

Age Group:

< 40

3

15

2 (22)

1 (9)

40-49

2

10

1 (11)

1 (9)

50-59

6

30

2 (22)

4 (36)

≥ 60

9

45

4 (44)

5 (46)

Initial HER2 Status:

0

6

30

1 +

1

5

NA

NA

2 +

0

0

3 +

13

65

Hercept Test HER2 Status:

0

4

20

1 +

7

35

NA

NA

2 +

2

10

3 +

7

35

Estrogen Status:

Positive

20

100

9 (100)

11 (100)

30% ER+ cells

0 (0)

0 (9)

70% ER+ cells

1 (11)

0 (0)

80% ER+ cells

2 (22)

1 (9)

90% ER+ cells

2 (22)

4 (36)

95% ER+ cells

2 (22)

2 (18)

100% ER+ cells

2 (22)

2 (18)

% cell not recorded

0 (0)

0 (0)

Negative

0

0

Progesterone Status:

Positive

19

95

9 (100)

10 (91)

Negative

1

5

0 (0)

1 (9)

Nodes Positive:

1-3

10

50

5 (56)

5 (46)

4-9

6

30

2 (22)

4 (36)

≥ 10

4

20

2 (22)

2 (18)

Predominant Tumor Histology:

Ductal

20

100

9 (100)

11 (100)

Lobular

0

Nottingham Grade:

2

11

55

4 (44)

8 (73)

3

9

45

5 (56)

3 (27)

Stage:

2

12

60

5 (56)

7 (64)

3

8

40

4 (44)

4 (36)

Pathologic Tumor Size:

< 2 cm

5

25

3 (33)

2 (18)

≥ 2 cm

15

75

6 (67)

9 (82)

Year of Block Procurement:

1998-2000

3

15

22 (22)

1 (9)

2001-2003

11

55

4 (44)

7 (64)

2004-2006

6

30

3 (33)

3 (27)


Reinholz et al. BMC Medical Genomics 2010 3:60   doi:10.1186/1755-8794-3-60

Open Data